Why are over-the-counter medicine prices holding steady?

The short answer

• Over-the-counter medicine prices fell 0.9 percent over the 12 months to September 2026 as record consumer adoption of store brands and aggressive price competition among mass retailers outpaced earlier inflation. [1] [2]
• While prices remain 12.2 percent higher than five years ago due to severe 2022–2023 supply pinches and input inflation, supply chain normalization and inventory discounting have kept nonprescription drug price growth far below the broader 3.7 percent inflation rate. [3] [4]

What's driving the price

Political, regulatory and trade factors

• Proposed removal of oral phenylephrine decongestants (Nov 2024 to Sep 2026), Food and Drug Administration: Following an advisory committee finding that oral phenylephrine was ineffective, the Food and Drug Administration issued a proposed administrative order on November 7, 2024, to delist it from over-the-counter monographs, prompting drugmakers and retailers to discount and clear out inventory of affected sinus and cold remedies ahead of mandatory reformulation deadlines. [pushed prices down] [5] [6]

Macro factors: supply, weather, disease, energy

• Supply chain normalization after pandemic respiratory shortages (Jan 2024 to Sep 2026): Production volumes for essential pediatric and adult fever and cough medicines fully stabilized following severe shortages during the 2022–2023 respiratory virus surges, removing the scarcity pricing premiums that drove earlier price spikes. [pushed prices down] [4]
• Cumulative packaging and ingredient cost shocks (Sep 2021 to Dec 2023): The 12.2 percent rise over five years was driven by earlier surges in active pharmaceutical ingredient procurement, energy, and resin-based blister packaging costs that manufacturers passed through to retail list prices during 2022 and 2023. [pushed prices up] [3] [8]

Retail, brand and seasonal factors

• Rapid market penetration of private label store brands (Oct 2024 to Sep 2026): Data from Circana and the Private Label Manufacturers Association showed store brands reaching a record 23.5 percent unit share and saving consumers 35 billion dollars in 2025, forcing major pharmaceutical brands to widen discounts and expand promotional pricing to protect shelf space. [pushed prices down] [2]
• Channel shift toward big-box discounters and online sellers (Jan 2025 to Sep 2026): Retail consolidation and thousands of closures at traditional pharmacy chains pushed consumer purchases toward mass retailers like Walmart, Costco, and Amazon, where bulk packaging and lower retail margins exerted downward pressure on retail prices. [pushed prices down] [7]

Supply chain right now

• Active pharmaceutical ingredient synthesis (stable): Global production capacity in India and China for commodity pain relievers and antihistamines is running smoothly with steady raw material costs. [9]
• Drug formulation and packaging (moderate): Manufacturers face compliance and transition expenses to reformulate cough and cold products around regulatory changes while baseline packaging costs remain steady. [6] [8]
• Wholesale distribution and warehousing (stable): Domestic freight logistics and warehouse operations have normalized following post-pandemic distribution backlogs. [4]
• Retail sales and pharmacy dispensing (moderate): Intense pricing pressure between mass-market retailers and declining drugstore footprints continues to compress retail markups. [7]

Researched 2026-10-18 with Google Search. Every point links to its sources; unsourced claims were removed.

Over-the-counter medicine prices, last 12 months

Source: U.S. Bureau of Labor Statistics, Consumer Price Index (CPI-U), series CUUR0000SEMF02.

Sources

1. Price Gap Growing Between Private Label and National Brands; 99% of U.S. Households Now Purchasing Private Label Products, Numerator Reports (numerator.com)
2. Store Brand Facts (plma.com)
3. Nonprescription Drugs Inflation by Year, 2009–2026: CPI Calculator (in2013dollars.com)
4. 152+ Pharma Supply Chain Statistics (2026) - PLAIO (plaio.com)
5. FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review (fda.gov)
6. FDA’s Proposal to Remove Oral Phenylephrine from the OTC Monograph Isn’t a Surprise but What is Left “Over-the-Counter”? (thefdalawblog.com)
7. Pharmaceutical OTC brands are being outcompeted by private-label OTC brands in retail and e-commerce marketplaces (biopharmadive.com)
8. Healthcare supply chain, pharmacy costs to rise in 2025: report (healthcaredive.com)
9. Active Pharmaceutical Ingredient Market Analysis | 2025-2030 (nextmsc.com)

More in Health

• Why are health insurance costs down 9% from a year ago?
• Why are prescription drug prices down 4.5% from a year ago?
• Why are doctors' fees rising slower than inflation?
• Why are dental costs up 6% from a year ago?
• Why are eye care costs rising slower than inflation?
• Why are hospital costs up 6% from a year ago?